Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.89 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.78 |
| ▸ | FAAH | O00519 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | PPARG | P37231 | 4/20 | 0.72 |
| ▸ | PPARD | Q03181 | 3/20 | 0.72 |
| ▸ | PPARA | Q07869 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.72 |
| ▸ | FABP4 | P15090 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arachidonamide SCHEMBL542346 | 1.00 | CNR1 (1.00) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| Arachidonamide SCHEMBL542347 | 1.00 | CNR1 (1.00) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| Arachidonamide SCHEMBL25341372 | 0.96 | CNR1 (0.93) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL4805185 | 0.96 | KDM4E (0.96) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL4805179 | 0.96 | KDM4E (0.96) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL469455 | 0.96 | KDM4E (0.96) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL10445415 | 0.94 | KDM4E (1.00) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL571436 | 0.94 | KDM4E (1.00) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL469581 | 0.94 | KDM4E (1.00) | CNR1KDM4ESOAT1CYP3A4MEN1 | |
| SCHEMBL7626693 | 0.94 | KDM4E (1.00) | CNR1KDM4ESOAT1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12011433-B2 | Mofezolac derivatives as multi-functions selective COX-1 inhibitors | ITEL TELECOMUNICAZIONI S.R.L. (IT) | 2024-06-18 | — | — | US | disclosed |
| EP-3782990-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | Università degli Studi di Bari "Aldo Moro" (IT) | 2021-02-24 | — | — | EP | disclosed |
| US-20210023055-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | ITEL TELECOMUNICAZIONI S.R.L. (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20190111025-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | UNIVERSITÁ DEGLI STUDI DI BARI "ALDO MORO" (IT) | 2019-04-18 | — | — | US | disclosed |
| WO-2012032509-A2 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF | MEDWELL LABORATORIES LTD. (IL) | 2012-03-15 | — | — | WO | disclosed |
| US-20040132819-A1 | Appetite control method | ABBOTT LABORATORIES | 2004-07-08 | — | — | US | disclosed |
| EP-1406576-A1 | HAIR AND/OR SCALP TREATMENT COMPOSITIONS | UNILEVER PLC (GB) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004012727-A1 | COMPOSITIONS COMPRISING POLYSATURATED FATTY ACID (PUFAS) FOR THE CONTROL OF APPETITE AND BODY WEIGHT MANAGEMENT | ABBOTT LABORATORIES (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003007901-A1 | HAIR AND/OR SCALP TREATMENT COMPOSITIONS | UNILEVER PLC (GB) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002065997-A1 | ANTIPERSPIRANT OR DEODORANT COMPOSITIONS | UNILEVER PLC (GB) | 2002-08-29 | — | — | WO | disclosed |
| EP-0670826-B1 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-04-26 | — | — | EP | disclosed |
| US-5618955-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1997-04-08 | — | — | US | disclosed |
| EP-0670826-A4 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | YISSUM RES DEV CO (IL) | 1996-08-14 | — | — | EP | disclosed |
| EP-0670826-A1 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012466-A1 | FATTY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1994-06-09 | — | — | WO | disclosed |
| EP-0355842-A2 | External preparation | Sansho Seiyaku Co., Ltd. (JP) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023055-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | PTGS1, HMOX1, HMGB1 | CNR1 1214/4885KDM4E 980/4885SOAT1 4338/4885 |
| US-20190111025-A1 | MOFEZOLAC DERIVATIVES AS MULTI-FUNCTIONS SELECTIVE COX-1 INHIBITORS | PTGS1, HMOX1, HMGB1 | CNR1 1036/4885KDM4E 1049/4885SOAT1 4117/4885 |
| US-12011433-B2 | Mofezolac derivatives as multi-functions selective COX-1 inhibitors | PTGS1, HMOX1, HMGB1 | CNR1 1214/4885KDM4E 980/4885SOAT1 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.